[go: up one dir, main page]

AR107840A1 - INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g - Google Patents

INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g

Info

Publication number
AR107840A1
AR107840A1 ARP170100589A ARP170100589A AR107840A1 AR 107840 A1 AR107840 A1 AR 107840A1 AR P170100589 A ARP170100589 A AR P170100589A AR P170100589 A ARP170100589 A AR P170100589A AR 107840 A1 AR107840 A1 AR 107840A1
Authority
AR
Argentina
Prior art keywords
alkyl
cyclopropyl
methyl
optionally substituted
phosfatidylinositol
Prior art date
Application number
ARP170100589A
Other languages
English (en)
Inventor
Christian Tyrchan
Rhona Cox
Pavol Zlatoidsky
Konstantinos Karabelas
Matthew Perry
Jens Petersen
Nils Pemberton
Mickael Mogemark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR107840A1 publication Critical patent/AR107840A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1) en donde X es C(O) o SO₂; Y se selecciona de -CH₂-, -CH=CH-, -C(CH₂)-, -CH(CH₃)-, -CH₂CH₂, -CH(OH)-, -N=CH- o -C(O)-; R¹ es (3,3-dimetilbutan-2-ilo) o alquilo C₁₋₄, en donde dicho alquilo C₁₋₄ está opcionalmente sustituido con ciclopropilo y 0, 1, 2 ó 3 F; R² se selecciona de CH₃, NHR⁴, SO₂R⁵ o (1-metil-1H-pirazol-5-il)metilo; R³ se selecciona de los compuestos del grupo de fórmulas (2); R⁴ es C(O)CH₃ o SO₂R⁶; R⁵ se selecciona de (3-cianofenil)sulfamoílo, CH₃, N(CH₃)₂, NH₂, NHCH₂CF₃, NH(oxetan-3-ilo), NH-alquilo C₁₋₃, en donde dicho alquilo C₁₋₃ está opcionalmente sustituido con 0 - 3 F y 0 - 1 sustituyentes seleccionados independientemente de OCH₃, ciclopropilo o NH-cicloalquilo C₃₋₄, en donde dicho cicloalquilo puede estar sustituido con 0 - 2 F; R⁶ se selecciona de ciclopropilo, (1,3-dimetil-1H-pirazol-4-il)metilo o alquilo C₁₋₄, en donde dicho alquilo C₁₋₄ está opcionalmente sustituido con 0 - 1 sustituyentes seleccionados independientemente de OCH₃, NCH₃ o ciclopropilo; R⁷ se selecciona de H, Cl o CH₃; R⁸ se selecciona de -NH(C=O)CH₃, o un compuesto del grupo de fórmulas (3); R⁹ se selecciona de H, Cl o NH₂; R¹⁰ se selecciona de H o NH₂; R¹¹ se selecciona de C(O)NH₂, C(O)NHCH₃ o C(O)NHCH₂-fenilo; R¹² se selecciona de CO₂H, CO₂CH₂CH₃ o CO₂NH(CH₂)₃NH₂; R¹³ se selecciona de H o CH₃; Y se selecciona de N o CH; o una de sus sales farmacéuticamente aceptables.
ARP170100589A 2016-03-10 2017-03-09 INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g AR107840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662306328P 2016-03-10 2016-03-10

Publications (1)

Publication Number Publication Date
AR107840A1 true AR107840A1 (es) 2018-06-13

Family

ID=58264542

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100589A AR107840A1 (es) 2016-03-10 2017-03-09 INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g

Country Status (13)

Country Link
US (2) US10858355B2 (es)
EP (1) EP3426652B1 (es)
JP (1) JP6893520B2 (es)
KR (1) KR20180117693A (es)
CN (1) CN108779110B (es)
AR (1) AR107840A1 (es)
AU (1) AU2017229445B2 (es)
BR (1) BR112018068075A2 (es)
CA (1) CA3015893C (es)
EA (1) EA036388B1 (es)
MX (1) MX387125B (es)
TW (1) TWI746525B (es)
WO (1) WO2017153527A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
ES3053348T3 (en) * 2019-04-10 2026-01-21 Nanjing Zenshine Pharmaceuticals Co Ltd Phosphatidylinositol 3-kinase inhibitors
EP3980010A4 (en) 2019-06-04 2023-06-07 Arcus Biosciences, Inc. 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
CN115611883B (zh) * 2021-07-13 2025-03-28 生物岛实验室 一种双环结构的PI3Kα抑制剂及其制备方法和用途
CN119768404A (zh) * 2022-09-01 2025-04-04 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
EP4585596A4 (en) * 2022-09-09 2025-12-10 Shanghai Yingli Pharm Co Ltd Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025003330A1 (en) 2023-06-30 2025-01-02 Forschungsverbund Berlin E.V. Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1885356A2 (en) * 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
EA200801716A1 (ru) * 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
CN101484452A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
EP2327704A4 (en) * 2008-08-29 2012-05-09 Shionogi & Co RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
AU2010216219A1 (en) * 2009-02-17 2011-09-01 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
US20120040950A1 (en) * 2009-12-22 2012-02-16 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
CN104379573A (zh) * 2012-04-20 2015-02-25 艾伯维公司 异吲哚酮衍生物
US10301304B2 (en) 2013-09-25 2019-05-28 Vertex Pharmaceuticals Incorporated Selective inhibitor of phosphatidylinositol 3-kinase-gamma
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピラジン誘導体

Also Published As

Publication number Publication date
BR112018068075A2 (pt) 2019-01-08
US10858355B2 (en) 2020-12-08
KR20180117693A (ko) 2018-10-29
TW201808945A (zh) 2018-03-16
JP6893520B2 (ja) 2021-06-23
CN108779110A (zh) 2018-11-09
TWI746525B (zh) 2021-11-21
EP3426652B1 (en) 2021-12-01
CA3015893C (en) 2021-11-09
EA036388B1 (ru) 2020-11-03
EA201891931A1 (ru) 2019-04-30
WO2017153527A1 (en) 2017-09-14
AU2017229445B2 (en) 2019-07-11
AU2017229445A1 (en) 2018-10-25
MX387125B (es) 2025-03-18
US20210047312A1 (en) 2021-02-18
EP3426652A1 (en) 2019-01-16
JP2019507788A (ja) 2019-03-22
US20200299289A1 (en) 2020-09-24
CA3015893A1 (en) 2017-09-14
MX2018010894A (es) 2018-11-09
CN108779110B (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
AR107840A1 (es) INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
AR110922A1 (es) Compuestos inhibidores del vih
AR114948A1 (es) Compuestos de benzamida
AR109805A1 (es) Derivados de oxadiazol microbiocidas
AR111419A1 (es) Compuestos fusionados de indazol piridona como antivirales
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
AR108356A1 (es) Derivados aromáticos de sulfonamida
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR102426A1 (es) Compuestos de indolcarboxamida como inhibidores de btk
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
AR080859A1 (es) Derivados 1,2,4 triazolo-piridinicos inhibidores no nucleosidicos de la transcriptasa inversa, utiles para tratar infecciones por vih y composiciones farmaceuticas que los contienen.
AR112348A1 (es) Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR108185A1 (es) Amidas terciarias y método para su uso
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR100327A1 (es) Inhibidores de quinasa relacionados con tropomiosina
AR109950A1 (es) INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR101155A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
AR107570A1 (es) Compuestos químicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure